このページの翻訳は実験的なもので、現在開発中です。フィードバックを お待ちしております!
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E 将来の成長 Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E利益と収益がそれぞれ年間28.8%と17%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に23.4% 37.9%なると予測されています。
主要情報 Pharmaceuticals 収益成長 20.0% 収益成長率 17.3% 将来の株主資本利益率 23.6% アナリストカバレッジ Low
最終更新日 24 Jun 2024
今後の成長に関する最新情報
Consensus EPS estimates fall by 33% Jun 26
Price target increased by 15% to ج.م4.38 May 19
Consensus revenue estimates increase by 13% Apr 16
Price target increased by 12% to ج.م3.47 Apr 16
Price target increased by 24% to ج.م2.96 Feb 16
Price target increased by 7.3% to ج.م3.74 May 16
すべての更新を表示
Now 20% overvalued Jul 02
Consensus EPS estimates fall by 33% Jun 26
Now 23% overvalued Jun 13
Now 24% overvalued May 19
Price target increased by 15% to ج.م4.38 May 19
First quarter 2024 earnings released: EPS: ج.م0.038 (vs ج.م0.045 in 1Q 2023) May 15
Consensus revenue estimates increase by 13% Apr 16
Price target increased by 12% to ج.م3.47 Apr 16
Full year 2023 earnings released: EPS: ج.م0.15 (vs ج.م0.15 in FY 2022) Mar 23
New minor risk - Market cap size Mar 06
Price target increased by 24% to ج.م2.96 Feb 16
Investor sentiment improves as stock rises 20% Feb 14
Investor sentiment improves as stock rises 16% Jan 31
Investor sentiment improves as stock rises 16% Dec 06
Now 20% undervalued after recent price drop Sep 11
New major risk - Financial position Aug 23
New major risk - Earnings quality Aug 06
Price target increased by 7.3% to ج.م3.74 May 16
Now 20% undervalued after recent price drop Apr 10
Investor sentiment improves as stock rises 15% Apr 06
Now 22% undervalued after recent price drop Mar 13
Now 22% undervalued Jan 10
Price target increased to ج.م3.32 Nov 18
Less than half of directors are independent Nov 16
Price target decreased to ج.م3.07 Sep 21
Second quarter 2022 earnings released: EPS: ج.م0.053 (vs ج.م0.032 in 2Q 2021) Aug 18
Less than half of directors are independent Apr 27
Price target decreased to ج.م3.23 Mar 17
Full year 2021 earnings: EPS and revenues exceed analyst expectations Feb 25
Price target decreased to ج.م3.16 Jan 20
Third quarter 2021 earnings released Nov 21
Second quarter 2021 earnings released: EPS ج.م0.041 (vs ج.م0.026 in 2Q 2020) Aug 10
Price target decreased to ج.م4.85 Apr 29
Consensus EPS estimates fall to ج.م0.21 Mar 25
Full year 2020 earnings released Mar 03
Revenue beats expectations, earnings disappoint Mar 03
New 90-day low: ج.م3.25 Mar 01
New 90-day low: ج.م3.46 Feb 10
Revenue and earnings beat expectations Nov 16
Third quarter 2020 earnings released: EPS ج.م0.032 Nov 16
New 90-day low: ج.م3.54 Oct 18
New 90-day low: ج.م3.60 Sep 28
Analysts update estimates Aug 23
Earnings released Aug 21
Analysts update estimates Aug 20
業績と収益の成長予測 CASE:RMDA - アナリストの将来予測と過去の財務データ ( )EGP Millions 日付 収益 収益 フリー・キャッシュフロー 営業活動によるキャッシュ 平均アナリスト数 12/31/2026 3,960 716 385 N/A 3 12/31/2025 3,522 534 278 582 4 12/31/2024 2,793 360 352 437 2 3/31/2024 1,987 214 -389 -133 N/A 12/31/2023 1,922 223 -298 -44 N/A 9/30/2023 1,779 226 -424 -199 N/A 6/30/2023 1,615 221 -317 -101 N/A 3/31/2023 1,533 224 -169 -42 N/A 12/31/2022 1,484 229 -99 29 N/A 9/30/2022 1,487 254 22 160 N/A 6/30/2022 1,420 229 -94 234 N/A 3/31/2022 1,321 207 27 268 N/A 12/31/2021 1,246 166 3 241 N/A 9/30/2021 1,140 136 -69 173 N/A 6/30/2021 1,060 115 -5 87 N/A 3/31/2021 1,010 106 -185 -39 N/A 12/31/2020 960 97 -365 -164 N/A 9/30/2020 947 119 -350 -162 N/A 6/30/2020 947 105 -248 -83 N/A 3/31/2020 921 94 -143 -15 N/A 12/31/2019 894 82 -38 53 N/A 9/30/2019 853 85 -55 215 N/A 6/30/2019 815 90 -185 82 N/A 3/31/2019 810 110 -216 42 N/A 12/31/2018 806 129 -248 3 N/A 12/31/2017 628 89 N/A -17 N/A 12/31/2016 382 27 N/A 25 N/A 12/31/2015 278 10 N/A 25 N/A
もっと見る
アナリストによる今後の成長予測
収入対貯蓄率: RMDAの予測収益成長率 (年間28.8% ) は 貯蓄率 ( 14.3% ) を上回っています。
収益対市場: RMDAの収益 ( 28.8% ) はEG市場 ( 14.7% ) よりも速いペースで成長すると予測されています。
高成長収益: RMDAの収益は今後 3 年間で 大幅に 増加すると予想されています。
収益対市場: RMDAの収益 ( 17% ) EG市場 ( 13.9% ) よりも速いペースで成長すると予測されています。
高い収益成長: RMDAの収益 ( 17% ) 20%よりも低い成長が予測されています。
将来の株主資本利益率
将来のROE: RMDAの 自己資本利益率 は、3年後には高くなると予測されています ( 23.4 %)
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.